08:00 , Jan 18, 2016 |  BC Week In Review  |  Clinical News

FF-10501: Preliminary Phase I/II data

Preliminary data from 17 patients with relapsed or refractory myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) in the Phase I portion of an open-label, dose-escalation, U.S. Phase I/II trial showed that twice-daily 50-400 mg/m...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Clinical News

FF-10501: Phase I/IIa started

Fujifilm's Fujifilm Corp. subsidiary began an open-label, dose-escalation, U.S. Phase I/IIa trial of oral FF-10501 given twice daily for the first 14 days of a 28-day cycle in about 56 patients with relapsed or refractory...